11 mai 2017
Plant Cell Cultures - A New Host for Biomanufacturing
Attention cette conférence est en anglais
Traditional methods for production of biologics use genetically modified E. coli, yeast, insect or mammalian cell cultures in bioreactor systems. For applications where a human therapeutic protein (monoclonal antibodies, vaccines, bioscavengers, replacement biologics) produced under cGMP conditions is required, plant cell cultures offer a number of advantages over currently used bioreactor-based systems, including low risk of contamination by mammalian viruses, blood-borne pathogens, prions, bacterial endotoxins or mycoplasma, the ability to perform complex glycosylation, ease of culturing compared with other higher eukaryotic hosts, the ability to target the product to the extracellular medium, and the ability to grow in simple, low cost, chemically defined and animal component-free medium.
In addition, semi continuous operation of plant cell bioreactors allows independent optimization of growth and production phases. Long term operation (up several months) is also possible by maintaining viable biomass within the bioreactor, thereby reducing the need for long seed trains, as well as minimizing turn-around time, CIP and SIP operations, chemicals and energy. Several example semi continuous bioreactor systems will be described that utilize different inducible expression systems in rice and tobacco cell cultures.
Speaker : Karen McDONALD, Professor in Department of Chemichal Engineering at the University of California, Davis, USA.
Her research group applies synthetic biology tools in plants for the development of novel expression systems as well as applying bioprocess engineering technologies to produce recombinant proteins (including human therapeutic proteins, enzymes for cellulose degradation, and biopolymers for materials applications) using whole plants, harvested plant tissues, and plant cells grown in vitro in bioreactors. From 2006-2013, She was the PI and Director of the NSF CREATE-IGERT, an interdisciplinary graduate training program focused on applications of plant biotechnology to biopharmaceuticals, biorefineries and sustainable agriculture. At the graduate level she teaches Biotechnology Fundamentals and Application, a required course for the Designated Emphasis in Biotechnology. At the undergraduate level she teaches courses in Biotechnology Facility esign and Regulatory Compliance as well as Engineering Economics and our Senior Capstone Design Course for our Biochemical Engineering major.
Over the past 31 years her research has generated over 70 referred journal articles, three issued patents and four patent applications in plant-based expression of recombinant proteins, with practical applications in human therapeutics, subunit vaccines, biodefense agents and biomaterials for medical applications. In 2013, she cofounded Inserogen, Inc., a Davis-based startup focused on plant-made biologics for rare diseases, with a former PhD student, Dr. Lucas Arzola. She is also the Faculty Director and Co-PI for our NSF ADVANCE program aimed at improving recruitment, retention and advancement of women faculty in STEM disciplines.